Important Update for uniQure Investors: Securities Class Action Deadline Approaching

Important Alert for uniQure Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is notifying investors in uniQure N.V. (NASDAQ: QURE) of an impending deadline related to a securities class action lawsuit. If you acquired securities of uniQure between September 24, 2025, and October 31, 2025, you should be aware that the deadline for seeking to be named the lead plaintiff in this case is fast approaching on April 13, 2026.

The investigation focuses on claims that the leadership of uniQure violated federal securities laws by making misleading statements regarding the company’s research and development activities, particularly concerning the FDA approval process for its Pivotal Study. Allegedly, they hid crucial information about the study's design and the approval status, as well as the impact of these factors on their timeline for filing a Biologics License Application (BLA).

On November 3, 2025, uniQure's stock dropped dramatically—over 49%—after the company revealed that the FDA no longer considered the previously shared study data sufficient for BLA submission. This disclosure contradicted earlier statements emphasizing the near-term potential for accelerated approval for their treatment candidate, AMT-130. The fallout from this news has raised significant concerns among shareholders regarding the transparency and reliability of information communicated by the company.

Faruqi & Faruqi partner, Josh Wilson, highlighted the importance of this deadline, urging investors who have suffered losses to act promptly. He encourages those who believe they may have a claim to reach out directly for further discussions on their options. The firm has a notable track record of securing hundreds of millions in recoveries for investors, positioning them as a formidable ally in navigating these complex legal waters.

Investors should also note that participation in this class action does not require active involvement as a lead plaintiff. Individuals can choose to claim their rights in the lawsuit without assuming this role. However, remaining informed and proactive is essential, especially as the investor group seeks to hold uniQure accountable for its disclosures.

Faruqi & Faruqi is committed to gathering information about the company's past conduct and welcomes input from whistleblowers, former employees, and shareholders who may have relevant information regarding the case. This collective intelligence could significantly strengthen the investor class's standing and potential for recovery.

To learn more about the particulars of the class action or to voice your concerns, you can visit Faruqi & Faruqi's dedicated webpage for uniQure or contact Josh Wilson directly.

In conclusion, with the approaching deadline in mind, affected investors should not hesitate to reach out for legal support. Being part of this class action may yield opportunities for financial recovery amid the uncertainties surrounding uniQure’s business practices. Until the deadline arrives, staying informed and connected will be vital for shareholders to safeguard their interests.

For further guidance, please visit Faruqi & Faruqi or contact them at 877-247-4292 or 212-983-9330 (Ext. 1310).